We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Occult Blood Test Increases Colon Cancer Screenings

By LabMedica International staff writers
Posted on 13 Aug 2013
A new study suggests that noninvasive fecal immunochemical tests (FIT) might be more effective in prompting participation in potentially lifesaving colorectal cancer (CRC) screening than colonoscopy, a more expensive and invasive procedure.

Researchers at UT Southwestern (Dallas, TX, USA) and the University of California, San Diego (UCSD, USA) identified 5,970 uninsured (undeserving) patients who were not up to date with CRC screening. More...
Mean patient age was 59 years, and 64% of patients were women. The sample populations was classified as 41% white, 24% black, 29% Hispanic, and 7% other race/ethnicity. The patients were subsequently assigned randomly to three groups.

One group was assigned to FIT outreach, consisting of mailed invitation to use and return an enclosed no-cost FIT (1,593 patients). A second was assigned to colonoscopy outreach, consisting of mailed invitation to schedule a no-cost colonoscopy (479 patients). The third group was assigned to usual care, consisting of opportunistic primary care visit–based screening (3,898 patients). In addition, the FIT and colonoscopy outreach groups received telephone follow-up to promote test completion. The main outcome measures were screening participation in any CRC test within one year.

The results showed that screening participation was significantly higher for both FIT (40.7%) and colonoscopy outreach (24.6%) groups than for usual care (12.1%). On analysis, screening was higher higher for FIT than for colonoscopy outreach among whites, blacks, and Hispanics. Rates of CRC identification and advanced adenoma detection were 0.4% and 0.8% for FIT outreach, 0.4%, and 1.3% for colonoscopy outreach, and 0.2% and 0.4% for usual care, respectively. Eleven of 60 patients with abnormal FIT results did not complete colonoscopy. The study was published in the August 5, 2013, edition of JAMA Internal Medicine.

“The study suggests that the best approach to offering and delivering screening to underserved populations may be through FIT,” said senior author Celette Sugg Skinner, MD, associate director of population science and cancer control at the UT Southwestern Cancer Center. “Questions for the future are whether superior participation can be maintained in the FIT group (because the test must be repeated every year) and how adherence rates will impact overall screening effectiveness and cost.”

FIT is a quick and easy test that requires no special preparation that is used to detect small amounts of occult blood in a patient's stool sample. Completed tests are then mailed to a laboratory for analysis.

Related Links:

UT Southwestern
University of California, San Diego



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.